investors

Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop
Allergan investors, rooting for a breakup, cheer rapastinel's phase 3 flop
Fierce Pharma
Allergan
investors
rapastinel
Flag link:
Biotech's big-bucks buybacks begin to burn
Biotech's big-bucks buybacks begin to burn
EP Vantage
investors
biotech
Big Biotech
stock buybacks
Flag link:
Clovis Oncology to Pay the SEC $20 Million for Misleading Investors
Clovis Oncology to Pay the SEC $20 Million for Misleading Investors
BioSpace
Clovis Oncology
SEC
investors
lung cancer
rociletinib
Flag link:
Theranos settles lawsuit from investors claiming they were defrauded
Theranos settles lawsuit from investors claiming they were defrauded
Marketwatch
Theranos
investors
Elizabeth Holmes
Flag link:
Watch out, Allergan. Activist investor David Tepper won approval to push a shake-up
Watch out, Allergan. Activist investor David Tepper won approval to push a shake-up
Fierce Pharma
investors
Allergan
David Tepper
FTC
Flag link:
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
Fierce Pharma
Shire
Pharma CEOs
executive pay
investors
Flemming Ornskov
Flag link:
Novartis investors demand action amid 'swamp' of bribery allegations in Greece
Novartis investors demand action amid 'swamp' of bribery allegations in Greece
Fierce Pharma
Novartis
investors
bribery
Greece
Flag link:
Sanofi investors hungry for drug progress and deal news
Sanofi investors hungry for drug progress and deal news
Reuters
Sanofi
investors
innovation
Flag link:
U.S. biotechs can’t shake October blues as investors await next moves
U.S. biotechs can’t shake October blues as investors await next moves
Globe and Mail, Canada
biotech
investors
Biogen
Gilead Sciences
Celgene
Flag link:
Allergan executives named in investor suit over alleged generics price fixing
Allergan executives named in investor suit over alleged generics price fixing
Fierce Pharma
Allergan
investors
generics
drug pricing
Flag link:
US Spinraza sales cause concern among Biogen investors
US Spinraza sales cause concern among Biogen investors
Biopharma Dive
Biogen
Spinraza
spinal muscular atrophy
investors
Flag link:
With just a little encouragement, biotech investors are ready to fall in love again
With just a little encouragement, biotech investors are ready to fall in love again
Endpoints
biotech
investors
AnaptysBio
Flag link:
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
Motley Fool
Gilead Sciences
Kite Pharma
M&A
investors
Flag link:
Activist investor pushing for Acorda sale
Activist investor pushing for Acorda sale
BioPharma Dive
Acorda
investors
M&A
Flag link:
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
Motley Fool
GW Pharma
earnings
investors
Flag link:
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
MannKind: Afrezza Television Ad Debuts; What Investors Need To Know
Seeking Alpha
MannKind
Afrezza
drug ads
diabetes
investors
inhaled insulin
Flag link:
Forget the science. These investors think they can pick biotech winners by algorithm
Forget the science. These investors think they can pick biotech winners by algorithm
Stat
investors
biotech
venture capital
Flag link:
3 Surprising Reasons Drug Stocks Tank Every Time the Republican Health Bill Hits a Snag
3 Surprising Reasons Drug Stocks Tank Every Time the Republican Health Bill Hits a Snag
Motley Fool
pharma stocks
healthcare reform
investors
Flag link:
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Endpoints
investors
AstraZeneca
Pascal Soriot
Imfinzi
tremelimumab
immuno-oncology
clinical trials
Flag link:
Mylan, embattled maker of EpiPen, faces a crucial test as angry investors plot to oust CEO
Mylan, embattled maker of EpiPen, faces a crucial test as angry investors plot to oust CEO
Stat
Mylan Labs
EpiPens
investors
Heather Bresch
Flag link:

Pages